BIOMARKER FOR HER2-POSITIVE CANCER AND ANTI-HER2 THERAPY AND USE THEREOF
作者： Joo Hyeong-Seok , Lee Jeong-Yeon , Kong Gu
DOI:
关键词:
摘要: The present invention provides MEL-18, which is a biomarker for human epidermal growth factor receptor2 (HER2) positive cancer and anti-HER2 therapy the use thereof. According to invention, MEL-18 prognostic predictor response of subject an targeted therapeutic agent in HER2+ can be used companion diagnostics HER2 subject, through administration ADAM 10/17 inhibitor or thereof combination with determined overcome resistance improve efficacy, thereby allowing effective cancer.
lens.org 参考文章(60)
Katharina Feldinger, Daniele Generali, Gabriela Kramer-Marek, Merel Gijsen, Tzi Bun Ng, Jack Ho Wong, Carla Strina, Mariarosa Cappelletti, Daniele Andreis, Ji-Liang Li, Esther Bridges, Helen Turley, Russell Leek, Ioannis Roxanis, Jacek Capala, Gillian Murphy, Adrian L. Harris, Anthony Kong, ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer Oncotarget. ,vol. 5, pp. 6633- 6646 ,(2014) , 10.18632/ONCOTARGET.1955
M. Kanno, M. Hasegawa, A. Ishida, K. Isono, M. Taniguchi, mel‐18, a Polycomb group‐related mammalian gene, encodes a transcriptional negative regulator with tumor suppressive activity. The EMBO Journal. ,vol. 14, pp. 5672- 5678 ,(1995) , 10.1002/J.1460-2075.1995.TB00254.X
Ralph Markus Wirtz, Marc Munnes, Methods and compositions for the prediction of response to trastuzumab containing chemotherapy regimen in malignant neoplasia ,(2007)
Dorothee Foernzler, Friedemann Krause, Paul Delmar, Stefan Scherer, Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer ,(2011)
Jordan S. Fridman, Xiangdong Liu, Gregory F. Hollis, Reid Huber, Phillip C. C. Liu, Steven M. Friedman, Timothy C. Burn, Peggy A. Scherle, Krishna Vaddi, Compositions, methods and kits relating to her-2 cleavage ,(2004)
Min-Hyung Cho, Ji-Hye Park, Hee-Joo Choi, Mi-Kyung Park, Hee-Young Won, Yeon-Ji Park, Chang Hoon Lee, Seung-Hyun Oh, Young-Soo Song, Hyun Sung Kim, Young-Ha Oh, Jeong-Yeon Lee, Gu Kong, DOT1L cooperates with the c-Myc-p300 complex to epigenetically derepress CDH1 transcription factors in breast cancer progression Nature Communications. ,vol. 6, pp. 7821- 7821 ,(2015) , 10.1038/NCOMMS8821
Michael J. Duffy, John Crown, Maeve Mullooly, ADAM10 and ADAM17: New Players in Trastuzumab Resistance Oncotarget. ,vol. 5, pp. 10963- 10964 ,(2014) , 10.18632/ONCOTARGET.2794
Maeve Mullooly, Patricia M McGowan, Susan A Kennedy, Stephen F Madden, John Crown, Norma O' Donovan, Michael J Duffy, ADAM10: a new player in breast cancer progression? British Journal of Cancer. ,vol. 113, pp. 945- 951 ,(2015) , 10.1038/BJC.2015.288
Lluis Morey, Alexandra Santanach, Enrique Blanco, Luigi Aloia, Elphège P. Nora, Benoit G. Bruneau, Luciano Di Croce, Polycomb Regulates Mesoderm Cell Fate-Specification in Embryonic Stem Cells through Activation and Repression Mechanisms Cell Stem Cell. ,vol. 17, pp. 300- 315 ,(2015) , 10.1016/J.STEM.2015.08.009
Jeong-Yeon Lee, Gu Kong, MEL-18, a tumor suppressor for aggressive breast cancer. Oncotarget. ,vol. 6, pp. 15710- 15711 ,(2015) , 10.18632/ONCOTARGET.4565